Mechanism-Based Pharmacokinetic Model for Paclitaxel
- 15 October 2001
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (20), 4065-4073
- https://doi.org/10.1200/jco.2001.19.20.4065
Abstract
PURPOSE: To create a model based on known mechanisms of paclitaxel distribution that could describe the pharmacokinetics (PK) of total and unbound plasma concentrations, as well as blood concentrat...Keywords
This publication has 16 references indexed in Scilit:
- Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patientsBritish Journal of Cancer, 1999
- Indirect-response model for the time course of leukopenia with anticancer drugs*Clinical Pharmacology & Therapeutics, 1998
- Linearized Colorimetric Assay for Cremophor EL: Application to Pharmacokinetics after 1-Hour Paclitaxel InfusionsAnalytical Biochemistry, 1998
- A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression*Clinical Pharmacology & Therapeutics, 1998
- Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1998
- Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMComputer Methods and Programs in Biomedicine, 1998
- Quantitation of Cremophor EL in Human Plasma Samples Using a Colorimetric Dye-Binding MicroassayAnalytical Biochemistry, 1998
- Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.Journal of Clinical Oncology, 1995
- The importance of modeling interoccasion variability in population pharmacokinetic analysesJournal of Pharmacokinetics and Biopharmaceutics, 1993
- Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.Journal of Clinical Oncology, 1993